case_images: PMC4361916_01
case_images: MRI disclosed a 15-mm mass in the liver (S8) with a low-signal intensity in T1-weighted image (inphase) (a), a high-signal intensity in T2-weighted image (b), and a strong high-signal intensity in the diffusion-weighted image (c).
case_images: cro-0008-0094-g01.jpg
case_images: PMC4361916_01_cro-0008-0094-g01.jpg
case_images: F1
case_images: MRI disclosed a 15-mm low-signal intensity mass in T1-weighted image (fig. 1a), a high-signal intensity mass in T2-weighted image (fig. 1b), and a very high-signal intensity mass in the diffusion-weighted image (fig. 1c) in the liver (S8).
case_images: Hepatic angiography in the early phase (a) and late phase (b) revealed a tumor stain in the anterior superior arteries. The mass in the liver (S8) was described as an enhanced lesion on CT during hepatic arteriography (c), a corona-like enhanced lesion on CT in the portal-venous phase (d), and a low-density lesion on CT during arterial portography (e).
case_images: cro-0008-0094-g02.jpg
case_images: PMC4361916_01_cro-0008-0094-g02.jpg
case_images: F2
case_images: Hepatic angiography disclosed a tumor stain in the arterial (fig. 2a) and late phase (fig. 2b) in the same area. The mass in the liver (S8) was described as an enhanced lesion on CT during hepatic arteriography (fig. 2c, d) and as a low-density lesion on CT during arterial portography (fig. 2e).
case_images: MRI revealed a 6-mm low-signal intensity mass in the liver (S8) in T1-weighted image (a) 2 months after the initial diagnosis. The gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI disclosed no mass in the arterial phase (b) and a 6-mm low-signal intensity mass in the hepatobiliary phase (c). MRI showed no mass in the liver (S8) in the pre-enhanced phase of T1-weighted image (d), arterial phase (e), and hepatobiliary phase (f) 6 months after the initial diagnosis.
case_images: cro-0008-0094-g03.jpg
case_images: PMC4361916_01_cro-0008-0094-g03.jpg
case_images: F3
case_images: Two months after the initial diagnosis, follow-up gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI showed a 6-mm low-signal intensity mass in T1-weighted image (fig. 3a), no mass in the arterial phase (fig. 3b), and a low-signal intensity mass in the hepatobiliary phase (fig. 3c). Six months after the initial diagnosis, follow-up ethoxybenzyl MRI showed no mass in the liver (S8) (fig. 3d-f), and the AFP serum level decreased to a normal range (5.0 ng/ml).